Attaining true transparency in drug trials calls for a better solution than excessive redaction. Learn the drawbacks and benefits of the different methods for anonymization in clinical trials. There is potential for strong industry leaders to emerge — so long as they align themselves with best practice guidelines. By making the right choices now, pharmaceutical organizations will meet the new transparency mandates while complying with privacy regulations and maximizing the quality of data that can be shared for secondary purposes.
Some organizations now say the expense of maintaining records systems exceeds the incentives. As more emphasis is placed on quality, EHRs will grow in importance and play a role in determining which rural providers survive.
Industry leaders, such as Micki Tripathi of the Massachusetts eHealth Collaborative, say that the system won’t add anything to current private sector initiatives to rate EHR products and charge that it may have a chilling effect on innovation.